CY1117357T1 - Υγρες φαρμακοτεχνικες μορφες για θεραπεια ασθενειων ή καταστασεων - Google Patents
Υγρες φαρμακοτεχνικες μορφες για θεραπεια ασθενειων ή καταστασεωνInfo
- Publication number
- CY1117357T1 CY1117357T1 CY20161100276T CY161100276T CY1117357T1 CY 1117357 T1 CY1117357 T1 CY 1117357T1 CY 20161100276 T CY20161100276 T CY 20161100276T CY 161100276 T CY161100276 T CY 161100276T CY 1117357 T1 CY1117357 T1 CY 1117357T1
- Authority
- CY
- Cyprus
- Prior art keywords
- subject
- liquid formulations
- disease
- therapeutic agents
- limited
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 239000007788 liquid Substances 0.000 title 1
- 239000012669 liquid formulation Substances 0.000 abstract 6
- 239000003814 drug Substances 0.000 abstract 5
- 229940124597 therapeutic agent Drugs 0.000 abstract 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 3
- 229960002930 sirolimus Drugs 0.000 abstract 3
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 239000012736 aqueous medium Substances 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 abstract 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65179005P | 2005-02-09 | 2005-02-09 | |
| US66430605P | 2005-03-21 | 2005-03-21 | |
| US66404005P | 2005-03-21 | 2005-03-21 | |
| EP06734887.0A EP1848431B1 (en) | 2005-02-09 | 2006-02-09 | Liquid formulations for treatment of diseases or conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117357T1 true CY1117357T1 (el) | 2017-04-26 |
Family
ID=36793384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100276T CY1117357T1 (el) | 2005-02-09 | 2016-04-06 | Υγρες φαρμακοτεχνικες μορφες για θεραπεια ασθενειων ή καταστασεων |
Country Status (17)
| Country | Link |
|---|---|
| US (11) | US8637070B2 (https=) |
| EP (3) | EP3025713A1 (https=) |
| JP (2) | JP4974903B2 (https=) |
| KR (3) | KR101492584B1 (https=) |
| CN (1) | CN104147005B (https=) |
| AU (2) | AU2006213673A1 (https=) |
| BR (2) | BRPI0608152A2 (https=) |
| CA (2) | CA2597596C (https=) |
| CY (1) | CY1117357T1 (https=) |
| DK (1) | DK1848431T3 (https=) |
| ES (1) | ES2564194T3 (https=) |
| GB (1) | GB2438544A (https=) |
| HK (1) | HK1222537A1 (https=) |
| HU (1) | HUE027352T2 (https=) |
| PL (1) | PL1848431T3 (https=) |
| SI (1) | SI1848431T1 (https=) |
| WO (2) | WO2006086750A1 (https=) |
Families Citing this family (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| KR20060085246A (ko) * | 2003-09-18 | 2006-07-26 | 마커사이트, 인코포레이티드 | 경공막 전달 |
| US8288362B2 (en) * | 2004-05-07 | 2012-10-16 | S.K. Pharmaceuticals, Inc. | Stabilized glycosaminoglycan preparations and related methods |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
| AU2006227116A1 (en) * | 2005-03-21 | 2006-09-28 | Santen Pharmaceutical Co., Ltd. | Drug delivery systems for treatment of diseases or conditions |
| US20060222596A1 (en) | 2005-04-01 | 2006-10-05 | Trivascular, Inc. | Non-degradable, low swelling, water soluble radiopaque hydrogel polymer |
| US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| AU2013200089B2 (en) * | 2006-02-09 | 2016-03-03 | Santen Pharmaceutical Co., Ltd | Stable formulations, and methods of their preparation and use |
| KR20140093764A (ko) * | 2006-02-09 | 2014-07-28 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
| US20070249546A1 (en) * | 2006-04-22 | 2007-10-25 | Sawaya Assad S | Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them |
| US7872068B2 (en) | 2006-05-30 | 2011-01-18 | Incept Llc | Materials formable in situ within a medical device |
| AU2007284801A1 (en) * | 2006-08-08 | 2008-02-21 | The Regents Of The University Of Californina | Salicylanilides enhance oral delivery of therapeutic peptides |
| WO2008022256A2 (en) * | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| US9205080B2 (en) | 2006-11-16 | 2015-12-08 | Transderm, Inc. | Methods of treating keratin hyperproliferation disorders using mTOR inhibitors |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| WO2008120249A1 (en) * | 2007-03-30 | 2008-10-09 | Sifi S.P.A. | Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| AU2014201863B2 (en) * | 2007-04-30 | 2017-02-02 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
| KR20100051811A (ko) * | 2007-07-20 | 2010-05-18 | 알콘, 인코퍼레이티드 | 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제 |
| WO2009018333A2 (en) * | 2007-07-30 | 2009-02-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells |
| ES2507078T3 (es) * | 2007-08-16 | 2014-10-14 | Santen Pharmaceutical Co., Ltd | Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad |
| ES2667945T3 (es) | 2007-10-08 | 2018-05-16 | Aurinia Pharmaceuticals Inc. | Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR |
| CA2702761A1 (en) * | 2007-11-01 | 2009-05-07 | Bausch & Lomb Incorporated | Non-aqueous water-miscible materials as vehicles for drug delivery |
| WO2009067217A1 (en) * | 2007-11-20 | 2009-05-28 | Ceramoptec Industries, Inc. | Pdt assisted scar prevention and vision correction |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| US20090275529A1 (en) * | 2008-05-05 | 2009-11-05 | Reiss Allison B | Method for improving cardiovascular risk profile of cox inhibitors |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| ES2645692T3 (es) | 2008-11-11 | 2017-12-07 | The Board Of Regents,The University Of Texas System | Microcápsulas de rapamicina y su uso para el tratamiento del cáncer |
| DE102008059201A1 (de) * | 2008-11-27 | 2010-06-02 | GÖPFERICH, Achim, Prof. Dr. | In situ präzipitierende Arzneistofflösungen |
| WO2010065024A1 (en) * | 2008-12-05 | 2010-06-10 | Kador Peter F | Topical treatment of cataracts in dogs |
| JP5890182B2 (ja) | 2009-02-12 | 2016-03-22 | インセプト エルエルシー | ヒドロゲルプラグによる薬物送達 |
| US9636255B2 (en) | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| JP2010260857A (ja) * | 2009-04-10 | 2010-11-18 | Santen Pharmaceut Co Ltd | シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤 |
| BRPI1010655A2 (pt) * | 2009-04-10 | 2019-09-03 | Qi Haiyan | novos agentes antienvelhecimento e métodos para identificá-los |
| US20120114637A1 (en) * | 2009-05-04 | 2012-05-10 | Santen Pharmaceutical Co., Ltd. | Mtor pathway inhibitors for treating ocular disorders |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| EP2432420A4 (en) | 2009-05-18 | 2018-01-10 | Dose Medical Corporation | Drug eluting ocular implant |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US9480645B2 (en) * | 2009-06-02 | 2016-11-01 | Abbott Medical Optics Inc. | Omega-3 oil containing ophthalmic emulsions |
| US20100305046A1 (en) * | 2009-06-02 | 2010-12-02 | Abbott Medical Optics Inc. | Stable cyclosporine containing ophthalmic emulsion for treating dry eyes |
| AU2014250656B2 (en) * | 2009-06-02 | 2016-05-05 | Johnson & Johnson Surgical Vision, Inc. | Omega-3 oil containing ophthalmic emulsions |
| US20100303915A1 (en) * | 2009-06-02 | 2010-12-02 | Abbott Medical Optics Inc. | Therapeutic opthalmic emulsions |
| EP2440185B1 (en) | 2009-06-09 | 2015-04-08 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
| CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| TWI492769B (zh) * | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
| EP2308468A1 (en) * | 2009-10-08 | 2011-04-13 | Novaliq GmbH | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| US9717703B2 (en) | 2009-10-16 | 2017-08-01 | Glaxosmithkline Llc | Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| WO2015161139A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| CA2786953A1 (en) | 2010-01-12 | 2011-07-21 | Florian Anders Foeger | Pharmaceutical compositions for oral administration of insulin peptides |
| US8961501B2 (en) * | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
| WO2012067224A1 (ja) * | 2010-11-19 | 2012-05-24 | 日本水産株式会社 | 角膜上皮障害及び／又は結膜上皮障害の治療又は予防剤 |
| EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
| KR101214362B1 (ko) * | 2011-02-15 | 2012-12-21 | 한림대학교 산학협력단 | Ｆｋ506 결합 단백질 융합 단백질을 함유하는 안과 질환 예방 및 치료용 점안제 조성물 |
| CN102653779B (zh) * | 2011-03-04 | 2014-02-19 | 北京科润三联生物技术有限责任公司 | 一种新型重组抗菌多肽药物的制备方法 |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
| US8716363B2 (en) | 2011-09-28 | 2014-05-06 | Globus Medical, Inc. | Biodegradable putty compositions and implant devices, methods, and kits relating to the same |
| CN103127052A (zh) * | 2011-12-05 | 2013-06-05 | 维瑞斯特姆有限公司 | 治疗组合物和相关使用方法 |
| JP6199883B2 (ja) | 2011-12-05 | 2017-09-20 | インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ | 医療用オルガノゲルプロセス及び組成物 |
| US8703786B2 (en) * | 2011-12-07 | 2014-04-22 | Texas Southern University | Etravirine formulations and uses thereof |
| WO2014059295A1 (en) | 2012-10-12 | 2014-04-17 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
| BR112015015788A2 (pt) | 2012-12-31 | 2017-07-11 | Jrx Biotechnology Inc | formulações farmacêuticas de nano-emulsão tópicas líquidas |
| WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| US9844597B2 (en) * | 2013-04-18 | 2017-12-19 | The Hong Kong University Of Science And Technology | Biocompatible in situ hydrogel |
| KR20160060656A (ko) | 2013-09-20 | 2016-05-30 | 산텐 세이야꾸 가부시키가이샤 | 폴리에틸렌글리콜 함유 조성물 |
| EP3089737B1 (en) * | 2013-12-31 | 2021-11-03 | Rapamycin Holdings, LLC | Oral rapamycin nanoparticle preparations and use |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| EP2946788A1 (en) | 2014-05-23 | 2015-11-25 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
| AU2015266850B2 (en) | 2014-05-29 | 2019-12-05 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2016054741A1 (en) * | 2014-10-08 | 2016-04-14 | Arivac Inc. | Altrenogest formulation and uses thereof for estrus synchronisation in animals |
| KR20240023714A (ko) * | 2015-02-02 | 2024-02-22 | 산텐 세이야꾸 가부시키가이샤 | 폴리아프론 및 이의 안검 투여 |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| CA2976952A1 (en) * | 2015-03-05 | 2016-09-09 | Allergan, Inc. | Self-emulsifying drug delivery system (sedds) for ophthalmic drug delivery |
| US11090296B2 (en) * | 2015-03-18 | 2021-08-17 | Santen Pharmaceutical Co., Ltd. | Sustained-release pharmaceutical composition |
| CA2986359A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US11260018B2 (en) | 2015-09-17 | 2022-03-01 | Jrx Biotechnology, Inc. | Approaches for improving skin hydration and moisturization |
| US20190038605A1 (en) * | 2015-09-18 | 2019-02-07 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof |
| MX393608B (es) * | 2015-09-18 | 2025-03-24 | Santen Pharmaceutical Co Ltd | Profilactico o agente terapeutico para queratitis fungica. |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| CA3055170A1 (en) | 2016-03-04 | 2017-09-08 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| AU2017252294B2 (en) | 2016-04-20 | 2021-12-02 | Glaukos Corporation | Bioresorbable ocular drug delivery device |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| US11400080B2 (en) | 2016-05-25 | 2022-08-02 | Santen Pharmaceutical Co., Ltd. | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema |
| SG11201811491YA (en) | 2016-06-27 | 2019-01-30 | Achillion Pharmaceuticals Inc | Quinazoline and indole compounds to treat medical disorders |
| US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| US10668011B2 (en) | 2016-06-30 | 2020-06-02 | Durect Corporation | Depot formulations |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| EA201990127A1 (ru) * | 2016-12-30 | 2020-08-18 | Дьюрект Корпорейшн | Депо-препарат |
| EP3565520B1 (en) * | 2017-01-06 | 2026-02-25 | Palvella Therapeutics, Inc. | Anhydrous compositions of mtor inhibitors and methods of use |
| US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
| AR111103A1 (es) * | 2017-02-17 | 2019-06-05 | Santen Pharmaceutical Co Ltd | Recipiente para sellado de formulaciones y uso del mismo |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US20210154372A1 (en) | 2017-05-15 | 2021-05-27 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
| US20200147055A1 (en) * | 2017-05-30 | 2020-05-14 | Eximore Ltd. | Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide |
| US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CA3067746A1 (en) | 2017-06-30 | 2019-01-03 | The Regents Of The University Of California | Compositions and methods for modulating hair growth |
| EP3656852B1 (en) | 2017-07-20 | 2025-09-03 | Riken | Method for maturation of retinal tissue containing continuous epithelium |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| EP4670713A1 (en) * | 2018-05-01 | 2025-12-31 | Chibi, Inc. | LIQUID DEPOSIT FOR THE PROLONGED NON-INVASIVE ADMINISTRATION OF AGENTS TO THE IL |
| US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| EP3866773B1 (en) | 2018-10-16 | 2024-08-28 | Georgia State University Research Foundation, Inc. | Carbon monoxide prodrugs for the treatment of medical disorders |
| EP3880266B1 (en) | 2018-11-14 | 2025-05-07 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
| IL283127B1 (en) * | 2018-11-14 | 2026-02-01 | Smilebiotek Zhuhai Ltd | Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders |
| CN113226309B (zh) * | 2018-12-03 | 2024-10-29 | 珠海岐微生物科技有限公司 | 一种治疗年龄相关性黄斑变性的方法 |
| WO2020150147A1 (en) * | 2019-01-14 | 2020-07-23 | The Regents Of The University Of California | Compositions and methods for treating ocular conditions |
| EP3952937A1 (en) | 2019-04-08 | 2022-02-16 | Bard Peripheral Vascular, Inc. | Medical device with drug-eluting coating on modified device surface |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| EP4028015A4 (en) | 2019-09-13 | 2023-11-15 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
| WO2021142317A1 (en) * | 2020-01-10 | 2021-07-15 | Briori Biotech, Llc | Topical compositions containing rofecoxib and methods of making and using the same |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| TW202146412A (zh) | 2020-03-05 | 2021-12-16 | 美商Ｃ４醫藥公司 | 用於標靶降解brd9之化合物 |
| CN116437913A (zh) | 2020-09-23 | 2023-07-14 | 艾其林医药公司 | 用于治疗补体介导的病症的药物化合物 |
| JP2024522808A (ja) * | 2021-06-21 | 2024-06-21 | パルヴェラ セラピューティクス、インク． | ゴーリン症候群を治療するための方法および組成物 |
| WO2023225373A1 (en) * | 2022-05-20 | 2023-11-23 | Dermbiont, Inc. | Compositions and formulations for use of a pk inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (270)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2007538A (en) * | 1934-04-10 | 1935-07-09 | Louis Stern Company | Bracelet end hook |
| US3416530A (en) | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3828777A (en) | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
| US3914402A (en) | 1973-06-14 | 1975-10-21 | Alza Corp | Ophthalmic dosage form, for releasing medication over time |
| US3926188A (en) | 1974-11-14 | 1975-12-16 | Alza Corp | Laminated drug dispenser |
| US4093709A (en) * | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
| US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| FR2382240A1 (fr) | 1977-03-03 | 1978-09-29 | Mouls Pierre | Dispositif permettant d'instiller des liquides medicamenteux dans l'oeil |
| US4300557A (en) | 1980-01-07 | 1981-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating intraocular malignancies |
| AU543727B2 (en) | 1980-06-02 | 1985-05-02 | Ayerst Mckenna & Harrison Inc. | Injectable composition of rapamycin |
| IT1141715B (it) | 1980-06-06 | 1986-10-08 | Sadepan Chimica Spa | Collante a base di resina urea-formaldeide additivato con ligninsolfonato di calcio e/o ammonio,resina urea formaldeide modificata con ligninsolfonato di calcio e/o ammonio e metodo di produzione degli stessi,per la preparazione di pannelli agglomerati di legno |
| US4316885A (en) * | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US5322691A (en) * | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
| US5147647A (en) | 1986-10-02 | 1992-09-15 | Sohrab Darougar | Ocular insert for the fornix |
| KR920003601B1 (ko) | 1987-09-03 | 1992-05-04 | 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 | 점안 싸이클로스포린(cyclosporin)의 조성물 |
| US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| EP0356399A3 (en) * | 1988-08-26 | 1991-03-20 | Sandoz Ag | Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them |
| US4946450A (en) | 1989-04-18 | 1990-08-07 | Biosource Genetics Corporation | Glucan/collagen therapeutic eye shields |
| US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5883082A (en) * | 1990-08-14 | 1999-03-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for preventing and treating allograft rejection |
| US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
| JPH04230389A (ja) | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
| DE4022553A1 (de) | 1990-07-16 | 1992-01-23 | Hund Helmut Gmbh | Vorrichtung zur hochreproduzierbaren applikation definierter volumina von loesungen und suspensionen diagnostisch oder therapeutisch wirksamer substanzen auf der cornea-oberflaeche |
| US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5290892A (en) * | 1990-11-07 | 1994-03-01 | Nestle S.A. | Flexible intraocular lenses made from high refractive index polymers |
| CA2054983A1 (en) | 1990-11-08 | 1992-05-09 | Sotoo Asakura | Suspendible composition and process for preparing the same |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| DE69231644T2 (de) * | 1991-04-26 | 2001-05-23 | Fujisawa Pharmaceutical Co., Ltd. | Verwendung von makrolid-verbindungen gegen augenerkrankungen |
| US5565560A (en) | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
| US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| US5120725A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
| ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5189042A (en) * | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
| US5457111A (en) | 1991-09-05 | 1995-10-10 | Abbott Laboratories | Macrocyclic immunomodulators |
| US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| US5679666A (en) | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| NZ251628A (en) * | 1992-03-30 | 1996-07-26 | American Home Prod | Aqueous insectable rapamycin solution; product containing concentrate and diluent solutions |
| US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| FR2690846B1 (fr) * | 1992-05-05 | 1995-07-07 | Aiache Jean Marc | Forme galenique pour administration oculaire et procede de preparation. |
| US5858340A (en) * | 1992-05-22 | 1999-01-12 | The Procter & Gamble Company | Cosmetic compositions |
| AU5092493A (en) | 1992-09-08 | 1994-03-29 | Allergan, Inc. | Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| US5601844A (en) * | 1992-11-18 | 1997-02-11 | Fujisawa Pharmaceutical Co., Ltd. | Sustained release medicinal preparation |
| CA2156065A1 (en) | 1993-03-17 | 1994-09-29 | Rolf Wagner | Macrocyclic amide and urea immunomodulators |
| GB2278780B (en) | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
| US5798355A (en) | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
| CA2472404A1 (en) * | 1993-07-19 | 1995-02-02 | Angiotech Pharmaceuticals, Inc. | Combination of stent and anti-angiogenic factor |
| WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| IL111003A0 (en) | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
| IL111004A (en) | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| US5516770A (en) * | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
| US5616588A (en) * | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
| US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| US5527907A (en) * | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| SK78196A3 (en) * | 1993-12-17 | 1997-02-05 | Sandoz Ag | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
| US5788687A (en) | 1994-02-01 | 1998-08-04 | Caphco, Inc | Compositions and devices for controlled release of active ingredients |
| US5516522A (en) * | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US5773021A (en) * | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
| NZ283658A (en) | 1994-04-04 | 1999-09-29 | William R Freeman | Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides) |
| US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
| US5621108A (en) * | 1994-12-05 | 1997-04-15 | Trustees Of The University Of Pennsylvania | Processes and intermediates for preparing macrocycles |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| EP0957949B1 (en) | 1995-05-14 | 2004-08-04 | Optonol Ltd. | Intraocular implant, delivery device, and method of implantation |
| US5696135A (en) | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| US5614547A (en) * | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
| US6037370A (en) | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| JPH0930966A (ja) | 1995-07-24 | 1997-02-04 | Gakuzo Tamura | 眼科用新規製剤 |
| CN1137680C (zh) | 1995-09-19 | 2004-02-11 | 藤泽药品工业株式会社 | 气雾剂组合物 |
| US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| EP0877554A1 (en) | 1995-10-31 | 1998-11-18 | Merck & Co., Inc. | Triterpene derivatives with immunosuppressant activity |
| GB9601120D0 (en) * | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| ATE296114T1 (de) | 1996-02-13 | 2005-06-15 | Searle & Co | Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten |
| US6034239A (en) | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| US5743274A (en) * | 1996-03-18 | 1998-04-28 | Peyman; Gholam A. | Macular bandage for use in the treatment of subretinal neovascular members |
| US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
| JP3309175B2 (ja) | 1996-03-25 | 2002-07-29 | 参天製薬株式会社 | タンパク性薬物含有強膜プラグ |
| JPH09315954A (ja) | 1996-05-30 | 1997-12-09 | Kita:Kk | 眼科手術後の眼組織混濁防止剤。 |
| GB9710962D0 (en) * | 1997-05-28 | 1997-07-23 | Univ Cambridge Tech | Polyketides and their synthesis |
| RU2123314C1 (ru) | 1996-06-27 | 1998-12-20 | Павлова Татьяна Вячеславовна | Способ постановки ирригационной системы в теноново пространство |
| PT956034E (pt) * | 1996-07-30 | 2002-12-31 | Novartis Ag | Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina |
| US6142969A (en) | 1996-10-25 | 2000-11-07 | Anamed, Inc. | Sutureless implantable device and method for treatment of glaucoma |
| US6007510A (en) | 1996-10-25 | 1999-12-28 | Anamed, Inc. | Implantable devices and methods for controlling the flow of fluids within the body |
| AUPO427196A0 (en) | 1996-12-19 | 1997-01-23 | University Of Sydney, The | A method for preventing or controlling cataract |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| JPH10218787A (ja) | 1997-02-06 | 1998-08-18 | Akio Okamoto | 神経栄養因子による眼科用組成物 |
| TW450810B (en) * | 1997-02-20 | 2001-08-21 | Fujisawa Pharmaceutical Co | Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| JP2001513369A (ja) | 1997-08-11 | 2001-09-04 | アラーガン・セイルズ・インコーポレイテッド | 改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法 |
| US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
| US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
| US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US6015815A (en) * | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| US20060198867A1 (en) | 1997-09-25 | 2006-09-07 | Abbott Laboratories, Inc. | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy |
| US20030190286A1 (en) | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
| DE69838338T2 (de) | 1997-10-22 | 2008-05-21 | Jens Rochester Ponikau | Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen |
| AR043071A1 (es) | 1997-10-31 | 2005-07-20 | Abbott Lab | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica |
| CZ287497B6 (cs) | 1997-12-30 | 2000-12-13 | Galena, A. S. | Topické oční přípravky s imunosupresivními látkami |
| WO1999037667A1 (en) | 1998-01-23 | 1999-07-29 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| DE19810655A1 (de) | 1998-03-12 | 1999-09-16 | Univ Eberhard Karls | Arzneimittel mit einem Gehalt an Ciclosporin |
| CA2321560C (en) | 1998-03-13 | 2007-05-22 | Johns Hopkins University School Of Medicine | The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation |
| AU3980499A (en) | 1998-05-11 | 1999-11-29 | Endowment for Research in Human Biology, Inc., The | Use of neomycin for treating angiogenesis-related diseases |
| US6399629B1 (en) * | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| ES2234266T3 (es) | 1998-07-24 | 2005-06-16 | Jago Research Ag | Formulaciones medicas para aerosoles. |
| US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| US7338976B1 (en) | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
| US6376517B1 (en) * | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
| US6384056B1 (en) | 1998-08-14 | 2002-05-07 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters or ketones for vision and memory disorders |
| US6632836B1 (en) | 1998-10-30 | 2003-10-14 | Merck & Co., Inc. | Carbocyclic potassium channel inhibitors |
| US6303637B1 (en) | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
| DK1143917T3 (da) | 1998-11-17 | 2004-06-01 | Ortho Mcneil Pharm Inc | Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom |
| GB9826882D0 (en) | 1998-12-07 | 1999-01-27 | Novartis Ag | Organic compounds |
| US6638522B1 (en) * | 1998-12-11 | 2003-10-28 | Pharmasolutions, Inc. | Microemulsion concentrate composition of cyclosporin |
| US6399655B1 (en) | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
| JP2002533412A (ja) * | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびコレステリルエステル転送タンパク質阻害剤の組み合わせ |
| US6864232B1 (en) * | 1998-12-24 | 2005-03-08 | Sucampo Ag | Agent for treating visual cell function disorder |
| NZ513111A (en) | 1998-12-24 | 2003-10-31 | R Tech Ueno Ltd | Agent for treating visual cell function disorder |
| EP1154691A4 (en) | 1999-01-05 | 2004-07-07 | Massachusetts Eye & Ear Infirm | TARGETED ADMINISTRATION OF REGULATED RELEASE MEDICINE TO RETINA AND CHOROID THROUGH SCLEROTIC |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US6254860B1 (en) | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
| US7063857B1 (en) * | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| WO2000066122A1 (en) | 1999-04-30 | 2000-11-09 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| KR20070058028A (ko) * | 1999-05-24 | 2007-06-07 | 소너스파머슈티칼즈인코포레이티드 | 난용성 약물용 에멀젼 부형제 |
| US6576224B1 (en) | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| JP2001064198A (ja) | 1999-08-24 | 2001-03-13 | Teika Seiyaku Kk | 角膜疾患治療剤 |
| KR20020063873A (ko) | 1999-10-18 | 2002-08-05 | 후지사와 야꾸힝 고교 가부시키가이샤 | 리포좀 제제의 제조방법 |
| US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| JP2003511204A (ja) | 1999-10-21 | 2003-03-25 | アルコン，インコーポレイティド | テノン下薬剤送出 |
| CA2383499C (en) | 1999-10-21 | 2009-11-24 | Alcon Universal Ltd. | Drug delivery device |
| EP1225879A2 (en) * | 1999-10-22 | 2002-07-31 | Orbon Corporation | Ophthalmic formulation of dopamine antagonists |
| DE60037822D1 (de) | 1999-10-22 | 2008-03-06 | Biogen Idec Inc | Verwendung eines cd40:cd154 bindungs-unterbrechers zur behandlung immunologischer komplikationen des auges |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| DE60033965T2 (de) | 1999-10-29 | 2008-01-10 | Kosan Biosciences, Inc., Hayward | Rapamycin analoge |
| RU2149615C1 (ru) | 1999-11-10 | 2000-05-27 | Нестеров Аркадий Павлович | Способ введения лекарственных препаратов при заболеваниях заднего отрезка глаза |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| CN1402629A (zh) | 1999-12-23 | 2003-03-12 | 辉瑞产品公司 | 提供提高的药物浓度的药物组合物 |
| GB0003932D0 (en) | 2000-02-18 | 2000-04-12 | Novartis Ag | Pharmaceutical compositions |
| US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| US6489335B2 (en) | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| EP1142566B1 (fr) | 2000-04-07 | 2003-10-01 | Laboratoire Medidom S.A. | Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate |
| US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
| CN1127955C (zh) | 2000-07-07 | 2003-11-19 | 中山医科大学中山眼科中心 | 一种眼前段及眼表免疫相关性疾病治疗药物 |
| DE60135352D1 (de) * | 2000-08-30 | 2008-09-25 | Univ Johns Hopkins | Vorrichtung zur intraokularen wirkstoffverabreichung |
| CN1204919C (zh) | 2000-08-30 | 2005-06-08 | 中国科学院化学研究所 | 长效环孢素眼内释药体系 |
| AU2001296558A1 (en) | 2000-10-03 | 2002-04-15 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
| US20050084514A1 (en) * | 2000-11-06 | 2005-04-21 | Afmedica, Inc. | Combination drug therapy for reducing scar tissue formation |
| US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
| EP1339438B1 (en) * | 2000-11-29 | 2005-10-19 | Allergan Inc. | Preventing transplant rejection in the eye |
| US20020086051A1 (en) | 2001-01-03 | 2002-07-04 | Santos Viscasillas | Sustained release drug delivery devices with coated drug cores |
| AU2002249958B2 (en) | 2001-01-16 | 2007-11-08 | Vascular Therapies, Inc. | Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
| US7181287B2 (en) * | 2001-02-13 | 2007-02-20 | Second Sight Medical Products, Inc. | Implantable drug delivery device |
| MX368013B (es) | 2001-02-19 | 2019-09-13 | Novartis Ag | Tratamiento de cáncer. |
| US6777000B2 (en) * | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
| US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| AR033151A1 (es) | 2001-04-12 | 2003-12-03 | Sucampo Pharmaceuticals Inc | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares |
| EP1387671A1 (en) * | 2001-05-03 | 2004-02-11 | MASSACHUSETTS EYE & EAR INFIRMARY | Implantable drug delivery device and use thereof |
| JP2002332225A (ja) | 2001-05-09 | 2002-11-22 | Lion Corp | 眼科用組成物 |
| EP1404297B1 (en) | 2001-06-12 | 2011-04-27 | The Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
| US7034037B2 (en) * | 2001-06-29 | 2006-04-25 | Ethicon, Inc. | Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin |
| US6787179B2 (en) | 2001-06-29 | 2004-09-07 | Ethicon, Inc. | Sterilization of bioactive coatings |
| WO2003004098A1 (en) * | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| WO2003007944A1 (en) | 2001-07-20 | 2003-01-30 | Qlt, Inc. | Treatment of macular edema with photodynamic therapy |
| TWI324925B (en) | 2001-08-23 | 2010-05-21 | Novartis Ag | Ophthalmic composition |
| US6812220B2 (en) | 2001-08-29 | 2004-11-02 | University Of British Columbia | Pharmaceutical compositions and methods relating to fucans |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US6656460B2 (en) | 2001-11-01 | 2003-12-02 | Yissum Research Development | Method and composition for dry eye treatment |
| US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| JP2005511576A (ja) * | 2001-11-09 | 2005-04-28 | アイテック・ファーマシューティカルズ | 眼球血管新生病を治療する方法 |
| US6663880B1 (en) * | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
| IL162496A0 (en) | 2001-12-14 | 2005-11-20 | Jagotec Ag | Pharmaceutical compositions containing cyclosporin |
| GB0200429D0 (en) * | 2002-01-09 | 2002-02-27 | Novartis Ag | Organic compounds |
| EP1480636B1 (en) | 2002-03-01 | 2007-04-18 | Novagali Pharma SA | Self emulsifying drug delivery systems for taxoids |
| WO2003074029A1 (en) | 2002-03-07 | 2003-09-12 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
| EP1485066B1 (fr) * | 2002-03-12 | 2016-09-21 | Ethypharm | Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives |
| CA2484976A1 (en) | 2002-05-03 | 2003-11-13 | The Queen Elizabeth Hospital Research Foundation Inc. | Method of inhibiting angiogenesis |
| CN1456350A (zh) | 2002-05-10 | 2003-11-19 | 刘继东 | 环孢素眼用凝胶 |
| NZ518997A (en) * | 2002-05-16 | 2004-12-24 | Interag | Injection formulation for parenteral administration of biodegradable implant for sustained release of active agent |
| US20040057958A1 (en) * | 2002-05-17 | 2004-03-25 | Waggoner David W. | Immunogenicity-enhancing carriers and compositions thereof and methods of using the same |
| US7026374B2 (en) * | 2002-06-25 | 2006-04-11 | Aruna Nathan | Injectable microdispersions for medical applications |
| CA2492153C (en) | 2002-07-16 | 2012-05-08 | Biotica Technology Limited | Production of polyketide fkbp-ligand analogues |
| AR040693A1 (es) | 2002-07-30 | 2005-04-13 | Wyeth Corp | Formulaciones parenterales |
| US7429619B2 (en) | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
| CA2495103A1 (en) | 2002-08-09 | 2004-02-19 | Sucampo Pharmaceuticals, Inc. | Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases |
| US20050031650A1 (en) | 2002-08-26 | 2005-02-10 | Ethypharm | Composition with gelling properties for the sustained delivery of bioactive substances |
| DK1539157T3 (da) | 2002-09-18 | 2013-10-07 | Univ Pennsylvania | Fremgangsmåde til hæmning af choroidal neovaskularisering |
| WO2004028477A2 (en) | 2002-09-29 | 2004-04-08 | Surmodics, Inc. | Methods for treatment and/or prevention of retinal disease |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| CN100453066C (zh) | 2002-12-04 | 2009-01-21 | 参天制药株式会社 | 利用结膜下储存库的药物释放系统 |
| WO2004060283A2 (en) | 2002-12-16 | 2004-07-22 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| WO2004062669A1 (en) | 2003-01-16 | 2004-07-29 | Sucampo Ag | Use of a macrolide compound for treating dry eye |
| WO2004074445A2 (en) | 2003-02-17 | 2004-09-02 | Cold Spring Harbor Laboratory | Model for studying the role of genes in tumor resistance to chemotherapy |
| US20050255144A1 (en) | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US20050074497A1 (en) | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| WO2004096261A1 (es) | 2003-05-02 | 2004-11-11 | Arturo Jimenez Bayardo | Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante |
| US7160867B2 (en) * | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
| DK1635875T3 (da) * | 2003-06-26 | 2009-01-12 | Psivida Inc | In-situ-geldannende lægemiddeladministrationssystem |
| US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| EP1510206A1 (en) | 2003-08-29 | 2005-03-02 | Novagali Pharma SA | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| KR20060085246A (ko) | 2003-09-18 | 2006-07-26 | 마커사이트, 인코포레이티드 | 경공막 전달 |
| US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| US20050181018A1 (en) | 2003-09-19 | 2005-08-18 | Peyman Gholam A. | Ocular drug delivery |
| US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
| US7402399B2 (en) | 2003-10-14 | 2008-07-22 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
| US20060141049A1 (en) | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| CA2536242A1 (en) * | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Implantable sensors and implantable pumps and anti-scarring agents |
| WO2005051316A2 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Polymer compositions and methods for their use |
| US7186518B2 (en) * | 2003-11-21 | 2007-03-06 | Dade Behring Inc. | Method and composition useful for determining FK 506 |
| WO2005055945A2 (en) | 2003-12-08 | 2005-06-23 | Gel-Del Technologies, Inc. | Mucoadhesive drug delivery devices and methods of making and using thereof |
| EP1720555A1 (en) | 2004-02-26 | 2006-11-15 | Advanced Ocular Systems Limited | Tetracycline derivatives for the treatment of ocular pathologies |
| US20050266442A1 (en) | 2004-03-25 | 2005-12-01 | Rachel Squillace | Immortalized human Tuberous Sclerosis null angiomyolipoma cell and method of use thereof |
| US7846940B2 (en) | 2004-03-31 | 2010-12-07 | Cordis Corporation | Solution formulations of sirolimus and its analogs for CAD treatment |
| PL1755616T3 (pl) | 2004-04-08 | 2014-10-31 | Eye Co Pty Ltd | Leczenie mineralokortykoidami retinopatii wysiękowej |
| US20050232965A1 (en) | 2004-04-15 | 2005-10-20 | Robert Falotico | Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20050250804A1 (en) | 2004-05-06 | 2005-11-10 | Glenmark Pharmaceuticals Limited | Pharmaceutical gel formulations |
| WO2006002399A2 (en) | 2004-06-24 | 2006-01-05 | Surmodics, Inc. | Biodegradable implantable medical devices, methods and systems |
| US20060024350A1 (en) * | 2004-06-24 | 2006-02-02 | Varner Signe E | Biodegradable ocular devices, methods and systems |
| WO2006002365A2 (en) | 2004-06-24 | 2006-01-05 | Angiotech International Ag | Microparticles with high loadings of a bioactive agent |
| WO2006080951A2 (en) * | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| WO2006014484A2 (en) | 2004-07-02 | 2006-02-09 | Surmodics, Inc. | Methods and devices for the treatment of ocular conditions |
| WO2006020755A2 (en) | 2004-08-10 | 2006-02-23 | Beth Israel Deaconess Medical Center, Inc. | Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics |
| US20060034891A1 (en) * | 2004-08-12 | 2006-02-16 | Laurie Lawin | Biodegradable controlled release bioactive agent delivery device |
| AR050374A1 (es) | 2004-08-20 | 2006-10-18 | Wyeth Corp | Forma polimorfica de rafampicina |
| CA2578245C (en) | 2004-08-27 | 2013-10-29 | Cardinal Health 529, Llc | Solvent free amorphous rapamycin |
| KR101341359B1 (ko) | 2004-10-01 | 2013-12-13 | 램스코르 인코포레이티드 | 편리하게 이식가능한 서방형 약물 조성물 |
| MX2007003789A (es) | 2004-10-04 | 2007-07-20 | Qlt Usa Inc | Suministro ocular de formulaciones polimericas para suministro. |
| EP1843805A4 (en) | 2004-11-09 | 2015-05-06 | Angiotech Pharm Inc | ANTIMICROBIAL NEEDLE COATING FOR ADVANCED INFUSION |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| CN101137369A (zh) * | 2005-02-09 | 2008-03-05 | 马库赛特公司 | 用于眼治疗的制剂 |
| DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
| GB0504995D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
| AU2006227116A1 (en) | 2005-03-21 | 2006-09-28 | Santen Pharmaceutical Co., Ltd. | Drug delivery systems for treatment of diseases or conditions |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| US8003124B2 (en) | 2005-04-08 | 2011-08-23 | Surmodics, Inc. | Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease |
| CA2606226A1 (en) | 2005-04-27 | 2006-11-02 | University Of Florida Research Foundation, Inc. | Materials and methods for enhanced degradation of mutant proteins associated with human disease |
| US20060247265A1 (en) | 2005-04-28 | 2006-11-02 | Clackson Timothy P | Therapies for treating disorders of the eye |
| JP2009500297A (ja) | 2005-06-08 | 2009-01-08 | セントカー・インコーポレーテツド | 眼の変性についての細胞療法 |
| US20070014760A1 (en) * | 2005-07-18 | 2007-01-18 | Peyman Gholam A | Enhanced recovery following ocular surgery |
| EP1904056B1 (en) | 2005-07-18 | 2009-04-29 | Minu, L.L.C. | Use of a macrolide to restore corneal sensation |
| US20070134244A1 (en) | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
| DE102006051512A1 (de) | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
| US20070173538A1 (en) | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| KR101411100B1 (ko) | 2006-01-23 | 2014-07-08 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. | 친지성 약물을 함유하는 나노캡슐을 포함하는 미소구체 |
| KR20140093764A (ko) | 2006-02-09 | 2014-07-28 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| JP2009528381A (ja) | 2006-02-28 | 2009-08-06 | パロマ ファーマシューティカルズ，インク． | 細胞増殖および血管新生を特徴とする疾患を治療する組成物および方法 |
| ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
-
2006
- 2006-02-09 DK DK06734887.0T patent/DK1848431T3/en active
- 2006-02-09 AU AU2006213673A patent/AU2006213673A1/en not_active Abandoned
- 2006-02-09 KR KR1020147002953A patent/KR101492584B1/ko not_active Expired - Fee Related
- 2006-02-09 KR KR1020077020500A patent/KR20070104931A/ko not_active Ceased
- 2006-02-09 CA CA2597596A patent/CA2597596C/en not_active Expired - Lifetime
- 2006-02-09 EP EP15198710.4A patent/EP3025713A1/en not_active Withdrawn
- 2006-02-09 JP JP2007555305A patent/JP4974903B2/ja not_active Expired - Fee Related
- 2006-02-09 CA CA002597590A patent/CA2597590A1/en not_active Abandoned
- 2006-02-09 EP EP06734887.0A patent/EP1848431B1/en not_active Expired - Lifetime
- 2006-02-09 BR BRPI0608152-5A patent/BRPI0608152A2/pt not_active IP Right Cessation
- 2006-02-09 CN CN201410320617.1A patent/CN104147005B/zh not_active Expired - Fee Related
- 2006-02-09 EP EP06720678A patent/EP1853259A1/en not_active Withdrawn
- 2006-02-09 PL PL06734887T patent/PL1848431T3/pl unknown
- 2006-02-09 KR KR1020077020502A patent/KR101387456B1/ko not_active Expired - Fee Related
- 2006-02-09 BR BRPI0607606-8A patent/BRPI0607606B1/pt not_active IP Right Cessation
- 2006-02-09 WO PCT/US2006/004962 patent/WO2006086750A1/en not_active Ceased
- 2006-02-09 US US11/352,092 patent/US8637070B2/en not_active Expired - Fee Related
- 2006-02-09 US US11/351,761 patent/US20060258698A1/en not_active Abandoned
- 2006-02-09 GB GB0715745A patent/GB2438544A/en active Pending
- 2006-02-09 ES ES06734887.0T patent/ES2564194T3/es not_active Expired - Lifetime
- 2006-02-09 HU HUE06734887A patent/HUE027352T2/en unknown
- 2006-02-09 SI SI200632038A patent/SI1848431T1/sl unknown
- 2006-02-09 AU AU2006213588A patent/AU2006213588B2/en not_active Ceased
- 2006-02-09 US US11/351,844 patent/US20060182771A1/en not_active Abandoned
- 2006-02-09 WO PCT/US2006/004955 patent/WO2006086744A1/en not_active Ceased
- 2006-02-09 JP JP2007555303A patent/JP2008530127A/ja active Pending
-
2010
- 2010-05-12 US US12/778,872 patent/US8367097B2/en active Active
-
2013
- 2013-01-14 US US13/741,103 patent/US8927005B2/en not_active Expired - Lifetime
-
2014
- 2014-01-09 US US14/151,647 patent/US9387165B2/en not_active Expired - Fee Related
- 2014-11-25 US US14/553,947 patent/US9381153B2/en not_active Expired - Lifetime
-
2016
- 2016-04-06 CY CY20161100276T patent/CY1117357T1/el unknown
- 2016-06-15 US US15/183,649 patent/US20170020809A1/en not_active Abandoned
- 2016-06-29 US US15/197,568 patent/US20160303093A1/en not_active Abandoned
- 2016-09-05 HK HK16110534.4A patent/HK1222537A1/en unknown
-
2017
- 2017-06-01 US US15/611,701 patent/US20170266109A1/en not_active Abandoned
- 2017-11-07 US US15/806,226 patent/US20180311152A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117357T1 (el) | Υγρες φαρμακοτεχνικες μορφες για θεραπεια ασθενειων ή καταστασεων | |
| WO2009023877A3 (en) | Formulations for treatment of ocular diseases or conditions | |
| BRPI0513243B8 (pt) | composições oftálmicas e respectivos usos | |
| NO20084199L (no) | Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom | |
| CY1117916T1 (el) | Θεραπεια διαταραχων που σχετιζονται me bdnf χρησιμοποιωντας laquinimod | |
| EP2427174A4 (en) | HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE | |
| NO20071267L (no) | Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer | |
| EA201491711A1 (ru) | Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов | |
| EA201100654A1 (ru) | Соединения для лечения офтальмологических заболеваний и расстройств | |
| CL2021003452A1 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades. | |
| WO2007035473A3 (en) | Pharmaceutical delivery device and method for providing ocular treatment | |
| EA201000441A1 (ru) | Водные офтальмологические препараты | |
| PA8603201A1 (es) | Procedimiento y composiciones farmaceuticas para el tratamiento de arterosclerosis, dislipidemias y afecciones relacionadas | |
| JP2014205721A5 (https=) | ||
| UY38765A (es) | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades | |
| BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
| BR112012030641B8 (pt) | Usos e composições para terapia farmacêutica oral | |
| MX2020010034A (es) | Metodo de tratamiento de enfermedad fibrotica. | |
| EP2424536A4 (en) | NEW PHOTOSENSIBILIZER FORMULATIONS FOR ORAL ADMINISTRATION | |
| BR0208962A (pt) | Método para liberar in vivo um oligonucleotìdeo quimérico para dentro de células alvo de um tecido humano ou animal, para tratar uma doença, para obter um modelo animal, para selecionar compostos cosméticos ou farmacêuticos, para tratar um hospedeiro humano possuindo retinopatia e para tratar um hospedeiro humano ou animal possuindo neovascularização ocular, aligonucleotìdeo quimérico, composição farmacêutica, modelo animal, e, uso do mesmo | |
| PA8624901A1 (es) | DERIVADOS DE BETA-AMINOACIDOS COMO INHIBIDORES DEL FACTOR Xa | |
| CY1106994T1 (el) | Φαρμακευτικη χρηση των cox-2 αναστολεων σε οφθαλμικες παθησεις που μεσολαβουνται απο αγγειογενεση | |
| ATE541567T1 (de) | Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| Lee et al. | Nerve growth factor expression in stroke induced rats after shock wave |